$APLS

Apellis Pharmaceuticals Showcases Significant Advances In Kidney Disease Treatment

$APLS Apellis Pharmaceuticals (NASDAQ:APLS) has recently presented compelling data from the Phase 3 VALIANT study, focusing on EMPAVELI® (pegcetacoplan) for…